comparemela.com
  1. Home
  2. Live Updates
  3. Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations : comparemela.com

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Ben Zeskind ,Gina Nugent ,Laurence Watts ,Immuneering Corporation Nasdaq ,Exchange Commission ,Immuneering Corporation ,Announces First Patient Dosed ,Treat Advanced Solid Tumors ,Cyclic Inhibitor ,Deep Cyclic Inhibitor ,Chief Executive Officer ,Deep Cyclic Inhibition ,Private Securities Litigation Reform Act ,Annual Report ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.